-

MTF Biologics Appoints George Herrera Executive Vice President of Donor Services

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science, today announced it has named George Herrera Executive Vice President, Donor Services. Herrera succeeds Martha Anderson, who is retiring on October 31, 2021, following a more than 30-year tenure with the organization.

In his new role, Herrera will oversee all public awareness initiatives related to tissue donation and provide strategic leadership and management to multiple MTF Biologics Divisions: Donor Services, International Institute for the Advancement of Medicine (IIAM) and Statline®. The Donor Services Division works to increase tissue donation and provides services to honor donor families and the gift of donation. IIAM advances scientific research and honors every donor’s legacy by providing non-transplantable organs and tissue to the medical research community. Statline is an electronic medical record systems for organizations involved in the organ, tissue and eye donation and transplantation fields.

Herrera joined MTF Biologics in 1997 as a Regional Director of Donor Services and most recently served as Vice President, Donor Services. During his tenure with the organization, he has advanced MTF Biologics’ donor programs and expanded its birth tissue capabilities. He has also been responsible for providing oversight to MTF Tissue Services located in upstate New York as well as many other critical services related to donor screening.

“George is perfectly suited to serve as MTF Biologics’ next EVP of Donor Services,” said Anderson. “He will seamlessly take on the roles and responsibilities that are so critical to our ability to serve our recovery partners, donors and their families and, ultimately, the thousands of tissue recipients who depend on our tissue to restore their health.”

Herrera serves on the Board of Directors of DonateLife America and served two terms on the American Association of Tissue Banks (AATB) Board of Governors. He is a frequent presenter at Association of Organ Procurement Organization (AOPO) meetings and is well recognized for his broad knowledge of the field of tissue and organ donation and transplantation.

Prior to MTF Biologics, Herrera served as the Director of Development at Louisiana Organ Procurement Agency where he was responsible for donor development and tissue sales and marketing. He also was Director of Development and Public Relations at the National Kidney Foundation of Louisiana.

Herrera received his Bachelor of Science in Marketing and Management from Tulane University and his Master of Business Administration from the University of New Orleans.

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. MTF Biologics’ sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit www.mtfbiologics.org.

Contacts

Kate Raley McIlroy
kate.raley@finnpartners.com

MTF Biologics


Release Versions

Contacts

Kate Raley McIlroy
kate.raley@finnpartners.com

More News From MTF Biologics

MTF Biologics’ AmnioBand® Membrane and AlloPatch® Pliable Confirmed as Covered Under Updated CMS Local Coverage Determinations

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts and advancing the science of tissue transplantation, today announced that two of its aseptically processed allografts without terminal irradiation, AmnioBand® Membrane, an allograft placental matrix, and AlloPatch® Pliable an allograft dermal matrix, will remain among the 18 tissues covered under the newly updated Medicare Local Coverage Determinations (LCDs) for sk...

MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS™ Sternal Repair Matrix for sternal fusion and IKON™ Allograft Surgical Matrix for soft tissue repair in high-risk patients. These hi...

MTF Biologics Completes First Implantation of FlexHD® Pliable in Milestone Breast Reconstruction Clinical Trial

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, today announced the successful implantation of FlexHD® Pliable in the first patient enrolled in its Investigational Device Exemption (IDE) clinical study for pre-pectoral breast reconstruction. This milestone pivotal study (SHAPE) aims to evaluate the safety and effectiveness of FlexHD® Pliable in implant-based breast rec...
Back to Newsroom